Grace Competitors
| GRCE Stock | 3.60 0.12 3.45% |
Grace Therapeutics vs ABVC Biopharma Correlation
Pay attention - limited upside
The correlation between Grace Therapeutics and ABVC is -0.82 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Grace Therapeutics and ABVC in the same portfolio, assuming nothing else is changed.
Moving together with Grace Stock
Moving against Grace Stock
| 0.8 | HPQ | HP Inc | PairCorr |
| 0.63 | MSFT | Microsoft | PairCorr |
| 0.45 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.42 | MMM | 3M Company | PairCorr |
| 0.4 | VLCN | Volcon Inc Symbol Change | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Grace Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Grace Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Grace Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Grace and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Grace Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Grace Stock performing well and Grace Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Grace Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| LVTX | 1.33 | 0.18 | 0.06 | 3.18 | 1.19 | 4.70 | 14.75 | |||
| TVRD | 2.78 | (0.34) | 0.00 | (0.18) | 0.00 | 5.59 | 17.90 | |||
| ATNM | 3.06 | (0.26) | 0.00 | (0.35) | 0.00 | 5.84 | 20.75 | |||
| PDSB | 4.16 | (0.43) | 0.00 | (0.12) | 0.00 | 8.08 | 27.78 | |||
| CALC | 6.46 | (1.09) | 0.00 | 2.19 | 0.00 | 12.74 | 105.18 | |||
| XLO | 2.22 | (0.73) | 0.00 | (0.64) | 0.00 | 4.17 | 15.41 | |||
| LTRN | 3.39 | (0.61) | 0.00 | (0.25) | 0.00 | 8.59 | 26.87 | |||
| OKUR | 3.88 | (0.38) | 0.00 | (0.30) | 0.00 | 7.76 | 25.44 | |||
| RNXT | 4.16 | (0.18) | (0.01) | 0.00 | 5.47 | 8.33 | 29.68 | |||
| ABVC | 3.32 | (0.84) | 0.00 | (0.44) | 0.00 | 7.31 | 23.14 |
Cross Equities Net Income Analysis
Compare Grace Therapeutics and related stocks such as LAVA Therapeutics, Tvardi Therapeutics, and Actinium Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVRD | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | (88.4 M) | (85.5 M) | (118.5 M) | (70.9 M) | (63.8 M) | (67 M) |
| ATNM | (18.4 K) | 10.3 K | (8.4 M) | (10.8 M) | (24.7 M) | (21 M) | (24.3 M) | (26.6 M) | (23.7 M) | (21.9 M) | (22.2 M) | (24.8 M) | (33 M) | (48.8 M) | (38.2 M) | (34.4 M) | (32.7 M) |
| PDSB | (4.7 M) | (4.7 M) | (4.7 M) | (6.9 M) | (12.2 M) | (28.1 M) | (38.8 M) | (50.9 M) | (40.9 M) | (7 M) | (14.8 M) | (16.9 M) | (40.9 M) | (42.9 M) | (37.6 M) | (33.8 M) | (35.5 M) |
| CALC | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (28.4 M) | (37 M) | (27.5 M) | (35.8 M) | (7.8 M) | (34.4 M) | (13.7 M) | (15.8 M) | (16.5 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (74.3 M) | (87.3 M) | (76.4 M) | (58.2 M) | (52.4 M) | (55 M) |
| LTRN | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (2.4 M) | (5.9 M) | (12.4 M) | (14.3 M) | (16 M) | (20.8 M) | (18.7 M) | (17.8 M) |
| OKUR | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (39.8 M) | (29.5 M) | (35.3 M) | (52.7 M) | (47.4 M) | (49.8 M) |
| RNXT | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (6.3 M) | (9.8 M) | (10.2 M) | (8.8 M) | (7.9 M) | (8.3 M) |
| ABVC | (20 K) | (1.2 M) | (24.1 K) | (24.1 K) | (24.1 K) | (32.3 K) | (11 M) | (4.2 M) | (5.6 M) | (3.6 M) | (9.8 M) | (12.8 M) | (16.4 M) | (7.8 M) | (4.9 M) | (4.4 M) | (4.6 M) |
Grace Therapeutics and related stocks such as LAVA Therapeutics, Tvardi Therapeutics, and Actinium Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Grace Therapeutics financial statement analysis. It represents the amount of money remaining after all of Grace Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Grace Therapeutics Competitive Analysis
The better you understand Grace Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Grace Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Grace Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Grace Therapeutics Competition Performance Charts
Five steps to successful analysis of Grace Therapeutics Competition
Grace Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Grace Therapeutics in relation to its competition. Grace Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Grace Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Grace Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Grace Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Grace Therapeutics position
In addition to having Grace Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Cap ETFs Thematic Idea Now
Small Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small Cap ETFs theme has 187 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Grace Therapeutics Correlation with its peers. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Will Pharmaceuticals sector continue expanding? Could Grace diversify its offerings? Factors like these will boost the valuation of Grace Therapeutics. Market participants price Grace higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Grace Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Grace Therapeutics requires distinguishing between market price and book value, where the latter reflects Grace's accounting equity. The concept of intrinsic value - what Grace Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Grace Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Grace Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.